According to data from cohort 17 of the phase 1b COSMIC-021 trial (NCT03170960), the combination therapy of cabozantinib and atelizumab, at a mean follow-up of 25.9 months, 17% of the 30 patients in cohort 17 had significant tumour shrinkage or disappearance, giving an overall disease control rate of 60% when those with stable lesions were added. 5 patients with tumours in remission All of the patients whose tumours had shrunk by at least 30%.
Medical
-
-
Although immortality is still only a myth in the mirror, living a long and healthy life is a goal that most people seem to be able to achieve.
-
The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.
-
In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.
-
Medical
Integrative Oncology: Acupuncture And Acupressure May Relieve Surgical Pain And Anxiety In Cancer Patients
For patients undergoing surgery for ovarian and endometrial cancer, pain and anxiety are often experienced. Recently, a new study has shown that acupressure before surgery may help reduce anxiety and that acupuncture during surgery may reduce severe pain. The study was published online in Cancer, a peer-reviewed journal of the American Cancer Society.
-
Medical
More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!
Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.
-
Can patients with bridge onychiasis and hypothyroidism have normal childbearing?
-
Medical
Good News, Orphan Drug Status Granted By The FDA For Ezurpimtrostat, a Cutting Edge Drug For Liver Cancer!
The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).
-
The pursuit of eternal beauty is the dream of every woman. For thousands of years, many people have made unremitting efforts to achieve the goal of beauty, so many stories about beauty have emerged.
-
Dry eye after excimer surgery is a common problem. The main reason for the occurrence of dry eye after surgery is that during excimer surgery, the production of corneal flap and the cutting of matrix cut off the sensory nerve of part of the cornea, reducing the sensory and neurotrophic functions of the cornea, leading to the reduction of reflective tear secretion and the number of blinks, which leads to the reduction of the amount of tear secretion and the stability of the tear film. The study found that the corneal nerve after surgery can be restored to the preoperative level after 6-9 months of regeneration and repair. Therefore, dry eye may be obvious at the early stage after surgery, but it will gradually reduce with corneal repair until it returns to normal.